REVIEW : PERBANDINGAN ANTARA TERAPI ANTIBIOTIK LEVOFLOXACIN JANGKA PENDEK DOSIS TINGGI DENGAN DOSIS REGIMEN KONVENSIONAL PADA PASIEN PNEUMONIA

Al-fira Putriyanti; Yani Mulyani; Salsha Rifa Isvahanie

doi:10.24198/farmaka.v22i3.56684

REVIEW : PERBANDINGAN ANTARA TERAPI ANTIBIOTIK LEVOFLOXACIN JANGKA PENDEK DOSIS TINGGI DENGAN DOSIS REGIMEN KONVENSIONAL PADA PASIEN PNEUMONIA

Al-fira Putriyanti, Yani Mulyani, Salsha Rifa Isvahanie

Abstrak

Pneumonia merupakan infeksi saluran pernapasan bawah yang menyebabkan inflamasi pada alveoli paru-paru. Penyebab pneumonia salah satunya oleh bakteri streptococcus pneumoniae. Pengobatan yang tepat dan cepat sangat penting untuk mengurangi morbiditas dan mortalitas yang terkait dengan penyakit ini. Pengobatan pneumonia bakterial sering melibatkan penggunaan antibiotik, dengan levofloxacin sebagai salah satu pilihan utama karena spektrum aktivitasnya yang luas. Namun, durasi optimal terapi antibiotik masih menjadi perdebatan, apakah terapi jangka pendek atau jangka panjang lebih efektif dalam mempercepat pemulihan pasien. Penelitian ini bertujuan untuk membandingkan efektivitas terapi antibiotik levofloxacin jangka panjang dan jangka pendek dalam masa waktu pemulihan pasien dengan pneumonia bakterial. Data dari berbagai studi klinis dan penelitian observasional dari tahun 2014 hingga 2024 dianalisis untuk mengevaluasi durasi optimal terapi dalam hal penyembuhan klinis, risiko kekambuhan, dan pengembangan resistensi antibiotik. Hasil penelitian menunjukkan bahwa terapi jangka pendek seringkali sama efektifnya dengan terapi jangka panjang dalam mencapai penyembuhan klinis, dengan keuntungan tambahan berupa pengurangan risiko efek samping dan resistensi antibiotik. Namun, terapi jangka panjang mungkin diperlukan untuk kasus dengan keparahan lebih tinggi atau komorbiditas tertentu untuk memastikan eradikasi patogen sepenuhnya. Temuan ini mengindikasikan bahwa durasi terapi antibiotik harus disesuaikan dengan kondisi klinis spesifik pasien untuk mencapai hasil optimal.

Teks Lengkap:

PDF

Referensi

Agarwal, A., Gao, Y., Colunga Lozano, L.E., Asif, S., Bakaa, L., Ghadimi, M., Basmaji, J., Das, A., Loeb, M., Guyatt, G., 2022. Shorter versus longer durations of antibiotic treatment for patients with community-acquired pneumonia: a protocol for a systematic review and meta-analysis. BMJ Open 12, e062428. https://doi.org/10.1136/bmjopen-2022-062428

Anzueto, A., Niederman, M.S., Pearle, J., Restrepo, M.I., Heyder, A., Choudhri, S.H., 2019. Erratum: Community-aquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy (Clinical Infectious Diseases (January 1, 2006) 42 (73-81)). Clin. Infect. Dis. 42, 1350.

Ben-Shimol, S., Levy-Litan, V., Falup-Pecurariu, O., Greenberg, D., 2014. Evidence for short duration of antibiotic treatment for non-severe community acquired pneumonia (CAP) in children — are we there yet? A systematic review of randomised controlled trials. Pneumonia 4, 16–23. https://doi.org/10.15172/pneu.2014.4/432

Carmen Pope, Bp., 2023. Levofloxacin: 7 things you should know [WWW Document]. drugs.com.

Chen, C.-W., Chen, Y.-H., Cheng, I.-L., Lai, C.-C., 2019. Comparison of high-dose, short-course levofloxacin treatment vs conventional regimen against acute bacterial infection: meta-analysis of randomized controlled trials. Infect. Drug Resist. 1353–1361.

Drugs.com., 2024. Levofloxacin Side Effects [WWW Document].

Dunbar, L.M., Wunderink, R.G., Habib, M.P., Smith, L.G., Tennenberg, A.M., Khashab, M.M., Wiesinger, B.A., Xiang, J.X., Zadeikis, N., Kahn, J.B., 2021. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin. Infect. Dis. 37, 752–760. https://doi.org/10.1086/377539

Furukawa, Y., Luo, Y., Funada, S., Onishi, A., Ostinelli, E., Hamza, T., Furukawa, T.A., Kataoka, Y., 2023. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open 13, e061023.

Gjini, E., Paupério, F.F.S., Ganusov, V. V, 2020. Treatment timing shifts the benefits of short and long antibiotic treatment over infection. Evol. Med. Public Heal. 2020, 249–263.

Hughes, S., Kamranpour, P., Gibani, M.M., Mughal, N., Moore, L.S.P., 2020. Short-course Antibiotic Therapy: A Bespoke Approach Is Required. Clin. Infect. Dis. 70, 1793–1794. https://doi.org/10.1093/cid/ciz711

Hyun, H., Song, J.Y., Yoon, J.G., Seong, H., Noh, J.Y., Cheong, H.J., Kim, W.J., 2022. Risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia: Microbiological distribution, antibiotic resistance, and clinical outcomes. PLoS One 17, e0270261.

Ishikawa, K., Masaki, T., Kawai, F., Ota, E., Mori, N., 2023. Systematic review of the short-term versus long-term duration of antibiotic management for neutropenic fever in patients with cancer. Cancers (Basel). 15, 1611.

Ito, A., Ishida, T., Tachibana, H., Nishiyama, A., Furuta, K., Tanaka, M., Tokioka, F., Yoshioka, H., Arita, M., Hashimoto, T., 2014. Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone. Eur. Respir. J. 44.

Jain, V., Vashisht, R., Yilmaz, G., Bhardwaj, A., 2018. Pneumonia pathology.

Krutikov, M., Rahman, A., Tiberi, S., 2019. Necrotizing pneumonia (aetiology, clinical features and management). Curr. Opin. Pulm. Med. 25, 225–232.

Lau, J.S.Y., Korman, T.M., Woolley, I., 2018. Life-long antimicrobial therapy: where is the evidence? J. Antimicrob. Chemother. 73, 2601–2612.

Llor, C., Bjerrum, L., 2014. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther. Adv. drug Saf. 5, 229–241.

Long, Y., Zheng, Y., Li, C., Guo, Z., Li, P., Zhang, F., Liu, W., Wang, Y., 2024. Respiratory pathogenic microbial infections: a narrative review. Int. J. Med. Sci. 21, 826.

Merative, M., 2024. Drugs and Supplements Levofloxacin (Oral Route) [WWW Document]. MAYO Clin.

Niederman, M.S., 2015. Macrolide-resistant pneumococcus in community-acquired pneumonia. Is there still a role for macrolide therapy? Am. J. Respir. Crit. Care Med.

Pahal, P., Rajasurya, V., Sharma, S., 2018. Typical bacterial pneumonia.

Podder, V., Sadiq, N.M., 2019. Levofloxacin.

Regunath, H., Oba, Y., 2017. Community-acquired pneumonia.

Ren, H., Li, X., Ni, Z.H., Niu, J.Y., Cao, B., Xu, J., Cheng, H., Tu, X.W., Ren, A.M., Hu, Y., Xing, C.Y., Liu, Y.H., Li, Y.F., Cen, J., Zhou, R., Xu, X.D., Qiu, X.H., Chen, N., 2017. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-i. Int. Urol. Nephrol. 49, 499–507. https://doi.org/10.1007/s11255-017-1507-0

Sattar, S.B.A., Sharma, S., Headley, A., 2021. Bacterial pneumonia (nursing).

Sharma, R., Sandrock, C.E., Meehan, J., Theriault, N., 2020. Community-acquired bacterial pneumonia—changing epidemiology, resistance patterns, and newer antibiotics: spotlight on delafloxacin. Clin. Drug Investig. 40, 947–960.

Su, Z.T., Zenilman, J.M., Sfanos, K.S., Herati, A.S., 2020. Management of Chronic Bacterial Prostatitis. Curr. Urol. Rep. 21, 29. https://doi.org/10.1007/s11934-020-00978-z

Torres, A., Menéndez, R., Wunderink, R.G., 2016. Bacterial pneumonia and lung abscess. Murray Nadel’s Textb. Respir. Med. 557.

Troeger, C., Forouzanfar, M., Rao, P.C., Khalil, I., Brown, A., Swartz, S., Fullman, N., Mosser, J., Thompson, R.L., Reiner, R.C., 2017. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect. Dis. 17, 1133–1161.

Truong, J., Ashurst, J. V, 2023. Pneumocystis jirovecii pneumonia, in: StatPearls [Internet]. StatPearls Publishing.

Vardakas, K.Z., Trigkidis, K.K., Apiranthiti, K.N., Falagas, M.E., 2017. The dilemma of monotherapy or combination therapy in community‐acquired pneumonia. Eur. J. Clin. Invest. 47, e12845.

DOI: https://doi.org/10.24198/farmaka.v22i3.56684

DOI (PDF): https://doi.org/10.24198/farmaka.v22i3.56684.g26042